Acadia Pharmaceuticals Inc.

Neuropsychiatric Disorders and Movement Disorders

The sponsor maintains a concentrated focus on addressing complex neuropsychiatric conditions associated with neurodegenerative diseases. Research efforts center on therapeutic interventions for Parkinson’s disease psychosis, a debilitating complication affecting patients with progressive motor disorders. The organization investigates treatment approaches for hallucinations and delusions that emerge in patients with established Parkinson’s disease, seeking to improve both psychiatric symptoms and overall quality of life.

  • Parkinson’s Disease Psychosis
  • Hallucinations and Delusions
  • Movement Disorder Complications

The therapeutic strategy emphasizes managing the psychiatric manifestations that frequently accompany motor symptoms in neurodegenerative conditions, representing a specialized area of expertise in addressing the intersection between movement disorders and psychiatric symptomatology.

Significant research activity addresses behavioral and psychological symptoms of dementia, with particular emphasis on Alzheimer’s disease-related psychosis. The sponsor explores therapeutic solutions for agitation in dementia, recognizing the substantial impact these symptoms have on patient care and caregiver burden. Investigation extends to various manifestations of dementia-related psychosis, including visual and auditory hallucinations, paranoid ideation, and behavioral disturbances.

  • Alzheimer’s Disease Psychosis
  • Dementia-Related Agitation
  • Behavioral Symptoms in Cognitive Decline

This therapeutic domain reflects a commitment to addressing the non-cognitive symptoms of neurodegenerative dementias, focusing on interventions that may reduce distressing psychiatric features while maintaining consideration for the vulnerable patient population affected by progressive cognitive impairment.

Central Nervous System Disorders

The organization pursues research into broader central nervous system pathologies, including investigations related to schizophrenia and associated psychotic disorders. Research encompasses conditions characterized by positive symptoms such as hallucinations and delusions, as well as the complex interplay between cognitive function and psychiatric manifestations. The therapeutic focus extends to understanding and treating disruptions in neurotransmitter systems that underlie various neuropsychiatric presentations.

  • Schizophrenia Spectrum Disorders
  • Psychotic Symptoms Management
  • Neurotransmitter Dysfunction

This research area demonstrates expertise in developing interventions for conditions involving altered dopaminergic and serotonergic signaling, with attention to both primary psychiatric disorders and secondary psychotic symptoms arising from neurological disease.

Rare Neurological Conditions

The sponsor demonstrates commitment to investigating therapeutic approaches for uncommon neurological disorders, including Rett syndrome, a rare genetic condition affecting neurological development predominantly in females. Research in this domain addresses the complex neurological and behavioral manifestations of rare neurodevelopmental disorders, seeking to improve functional outcomes and symptom management in conditions with limited treatment options.

  • Rett Syndrome
  • Genetic Neurodevelopmental Disorders
  • Pediatric Neurological Conditions

This therapeutic focus reflects an interest in addressing unmet medical needs within orphan neurological diseases, where conventional treatment paradigms may be insufficient and innovative approaches are critically needed to improve patient and family outcomes.

Psychiatric Symptom Management Across Neurological Conditions

A unifying theme across the research portfolio involves addressing psychiatric complications of neurological disease, with emphasis on conditions where traditional antipsychotic approaches may be contraindicated or inadequately effective. The organization explores interventions for secondary psychosis arising from primary neurological pathology, recognizing the distinct therapeutic challenges presented when psychiatric symptoms emerge in the context of progressive brain disease or structural neurological abnormalities.

  • Secondary Psychotic Disorders
  • Neuropsychiatric Complications
  • Quality of Life in Neurological Disease

This integrated approach to neuropsychiatric therapeutics emphasizes the need for specialized interventions that address psychiatric symptoms while considering the underlying neurological substrate, representing a sophisticated understanding of the complex relationship between brain structure, function, and behavior.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A Study of ACP-204 Tartrate for Adults With Lewy Body Dementia Psychosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Italy
  • A Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis

    Recruiting

    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Italy
  • Long-Term Safety Study of ACP-204 for Adults with Alzheimer’s Disease Psychosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Italy Spain
  • Study of ACP-204 for Treating Psychosis in Adults with Alzheimer’s Disease

    Recruiting

    Investigated drugs:
    Bulgaria Czechia France Italy Spain
  • Study on the Safety of Carbetocin Nasal Spray for Treating Uncontrollable Hunger in Patients with Prader-Willi Syndrome

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain
  • Study on the Long-Term Safety of Pimavanserin for Treating Irritability in Children and Adolescents with Autism Spectrum Disorder

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Hungary Italy Poland Spain